FDA Drug Recalls
359 recalls, newest first
Class II · Moderate risk Ongoing Jun 12, 2024
Reason Failed Dissolution Specifications - did not meet the acceptance criteria for IVR Level 3 testing at 9 months 2-8¿C followed by 6 weeks at 25¿C
Class II · Moderate risk Ongoing Jun 10, 2024
Reason Microbial Contamination of Non-Sterile Products: confirmed presence of mold contamination
Class III · Low risk Ongoing Jun 4, 2024
Reason Failed Impurities/Degradation Specifications: Related Substances
Class II · Moderate risk Ongoing Jun 4, 2024
Reason Subpotent Drug
Class II · Moderate risk Ongoing May 30, 2024
Reason CGMP Deviations
Class II · Moderate risk Ongoing May 30, 2024
Reason CGMP Deviations
Class I · High risk Ongoing May 30, 2024
Reason Failed Dissolution Specifications
Class I · High risk Ongoing May 30, 2024
Reason Failed Dissolution Specifications
Class I · High risk Ongoing May 28, 2024
Reason Presence of Particulate Matter: Presence of particulate matter from the stopper in the drug product.
Class I · High risk Ongoing May 28, 2024
Reason Presence of Particulate Matter: Presence of particulate matter from the stopper in the drug product.
Class III · Low risk Ongoing May 28, 2024
Reason Defective Container
Class III · Low risk Ongoing May 28, 2024
Reason Defective Container
Class III · Low risk Ongoing May 28, 2024
Reason Defective Container
Class II · Moderate risk Ongoing May 24, 2024
Reason CGMP Deviations
Class I · High risk Ongoing May 24, 2024
Reason Microbial Contamination of Non-Sterile Products: Presence of Aspergillus Sydowii (Mold)
Class II · Moderate risk Ongoing May 23, 2024
Reason Failed Impurities/Degradation Specifications: impurity sulfonic acid adduct of dexamethasone phosphate results were above spec.
Class II · Moderate risk Ongoing May 23, 2024
Reason Lack of Assurance of Sterility: Leaking vials
Class II · Moderate risk Ongoing May 22, 2024
Reason Marketed Without An Approved NDA/ANDA: FDA laboratory analysis found the product to contain undeclared diclofenac and methocarbamol,
Class III · Low risk Ongoing May 22, 2024
Reason Failed Impurities/Degradation Specifications: failed related substance identified as Eptifibatide dimer.
Class II · Moderate risk Ongoing May 20, 2024
Reason Discoloration: Brownish tablets
Class II · Moderate risk Ongoing May 20, 2024
Reason Lack of Assurance of Sterility-The potential for incomplete crimp seals.
Class II · Moderate risk Ongoing May 20, 2024
Reason Lack of Assurance of Sterility-The potential for incomplete crimp seals.
Class III · Low risk Ongoing May 16, 2024
Reason Failed Impurities/Degradation Specifications.
Class III · Low risk Ongoing May 16, 2024
Reason Failed Impurities/Degradation Specifications.
Class III · Low risk Ongoing May 16, 2024
Reason Presence of Foreign Tablets/Capsules: Complaint received from a re-packager, American Health Packaging (AHP), where a foreign tablet was discovered…